FDA Grants Breakthrough Designation to APR-246/Azacitidine Combo in TP53-Mutant MDS
OncLive,
The FDA has granted a breakthrough therapy designation to the combination of APR-246 and azacitidine for the treatment of…
Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Overview of attention for article published in Cancer Research, July 2018
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (81st percentile)
-
High Attention Score compared to outputs of the same age and source (90th percentile)
Readers on
- mendeley
- 8 Mendeley